Related Experiment Video
Updated: Aug 5, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
Continuous Glucose Monitoring in Children and Adolescents With Type 2 Diabetes: A Narrative Review
Cate O'Brien1, Kairavi Sethi1, Alexia Peña1,2
1Discipline of Paediatrics. Adelaide University and Robinson Research Institute, Women's and Children's Hospital, North Adelaide, South Australia, Australia.
Aim:
Continuous glucose monitoring (CGM) has well-established benefits in Type 1 diabetes; however, evidence in paediatric Type 2 diabetes (T2D) remains limited, and CGM is not currently publicly funded for this group in Australia. This review aimed to evaluate the impact of CGM use in adolescents with T2D.
Methods:
A systematic search of Ovid Medline, Embase, CINAHL and Emcare was conducted for studies published from database inception to 18 November 2025 that evaluated CGM use in children and adolescents with T2D. Outcomes included glycaemic measures (HbA1c and time in range [TIR]), patient-reported benefits and barriers and psychological outcomes.
Results:
Of 1019 manuscripts identified, eight studies met inclusion criteria. Study designs were longitudinal or cross-sectional, with relatively small sample sizes (7-41 participants). Five studies assessed HbA1c and TIR, two demonstrating short-term improvements that were not consistently sustained over time. Reported benefits included improved lifestyle behaviours, greater ease of diabetes management and increased frequency of glucose monitoring. Common barriers were sensor adhesion issues, connectivity challenges and concerns regarding wearability. Psychological outcomes were variable across studies.
Conclusions:
CGM use in children and adolescents with T2D is associated with transient improvements in glycaemic control and perceived benefits in daily diabetes management; however, technical and usability barriers limit sustained effectiveness. Structured education for children and families is essential to overcome these barriers and optimise long-term outcomes. Current evidence supports consideration of CGM funding for children and adolescents with T2D in Australia, alongside implementation of education programs to maximise benefit.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Hypoglycemia and Glucagon
Diabetes: Symptoms, Diagnosis, and Complications